Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Liposomal Chemotherapy

  • Mirco PonzoniEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3387-2



The central problem in cancer chemotherapy (Chemotherapy of Cancer, Progress and Perspectives) is the severe toxic side effects of anticancer drugs on healthy tissues. The use of liposomes as drug delivery vehicles (Drug delivery systems in cancer) for antitumor therapeutics has great potential to revolutionize the future of cancer therapy. As tumor architecture causes liposomes to preferentially accumulate at the tumor site, their use as drug carrier result in the localization of a greater amount of the drug load at the tumor site, thus improving cancer therapy and reducing the harmful nonspecific side effects of chemotherapeutics. In addition, targeting of liposomal anticancer drugs to antigens expressed or overexpressed on tumor cells provides a very efficient system for increasing the therapeutic indices of the drugs.


The Magic Bullet Concept

Within medical practice, there has long been the desire to achieve...


Malignant Pleural Mesothelioma Liposomal Doxorubicin Neoplastic Meningitis Liposomal Drug Conventional Liposome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763CrossRefPubMedGoogle Scholar
  2. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822CrossRefPubMedGoogle Scholar
  3. Corti A, Pastorino F, Curnis F, Arap W, Pasqualini R, Ponzoni M (2012). Targeted drug delivery and penetration into solid tumors. Med Res Rev 32(5):1078–91CrossRefPubMedGoogle Scholar
  4. Pastorino F, Brignole C, Marimpietri D et al (2003) Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63(1):86–92PubMedGoogle Scholar
  5. Pastorino F, Brignole C, Di Paolo D et al (2006) Targeting liposomal chemotherapy via both tumour cell-specific and tumour vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 66(20):10073–10082CrossRefPubMedGoogle Scholar
  6. Pastorino F, Brignole C, Loi M, Di Paolo D, Di Fiore A, Perri P, Pagnan G, Ponzoni M (2013). Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. Front Oncol 3:190CrossRefPubMedPubMedCentralGoogle Scholar
  7. Yezhelyev MV, Gao X, Xing Y et al (2006) Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7:657–667CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Experimental Therapies Unit, Laboratory of OncologyIstituto Giannina GasliniGenoaItaly